8.7 Packaging: PPPA Child-Resistant Containers, Waivers, Exemptions & Oregon's New-Container Rule
Key Takeaways
Under OAR 855-041-1145, an Oregon pharmacy must dispense every prescription in a new container that complies with the PPPA (16 CFR 1700–1702), so containers are not reused.
Under the PPPA, a patient may make a blanket request for non-child-resistant packaging, but a prescriber's request covers only that specific prescription.
PPPA exemptions include sublingual nitroglycerin, isosorbide dinitrate 10 mg or less, mnemonic-pack contraceptives, methylprednisolone of 84 mg or less per package and prednisone of 105 mg or less per package.
CPSC testing requires at least 80% of children aged 42–51 months to be unable to open a package and at least 90% of adults aged 50–70 to open and re-close it.
PPPA exemptions are tied to the package: a vial of tablets that exceeds the exemption limit needs a child-resistant closure.
Why this matters
Area 3.6 covers packaging of dispensed drugs. The core federal law is the Poison Prevention Packaging Act of 1970 (PPPA), enforced by the Consumer Product Safety Commission (CPSC) under 16 CFR 1700–1702. Oregon adopts it by reference and adds a new-container requirement (OAR 855-041-1145).
Oregon's container rule (OAR 855-041-1145)
Each pharmacy must dispense a drug in a new container that complies with the PPPA regulations in 16 CFR 1700, 1701 and 1702 (v. 01/01/2025). In Oregon, prescription containers are not reused. A refill goes into a new container even if the patient brings back a clean vial.
What the PPPA requires
Oral prescription drugs for human use, and many household substances, must be dispensed in special (child-resistant) packaging unless an exemption or waiver applies. Under the CPSC test protocol (16 CFR 1700.20):
- Child test: with a panel of children 42–51 months old, at least 85% must be unable to open the package in the first 5 minutes, and at least 80% after a demonstration in the next 5 minutes.
- Senior-adult test: with adults 50–70 years old, at least 90% must be able to open and properly re-close the package within 5 minutes.
Waivers
| Who | Scope |
|---|---|
| Patient (or agent) | May request non-child-resistant packaging for one prescription or all prescriptions (a blanket request). Pharmacies document it |
| Prescriber | May request non-child-resistant packaging only for that specific prescription. A prescriber cannot issue a blanket waiver for all of a patient's drugs |
| Pharmacist | Cannot waive child-resistant packaging on their own initiative |
Exemptions commonly tested (16 CFR 1700.14)
- Sublingual nitroglycerin.
- Sublingual and chewable isosorbide dinitrate in strengths of 10 mg or less.
- Oral contraceptives, conjugated estrogens and norethindrone acetate in mnemonic (calendar) dispenser packages, within the CPSC quantity limits.
- Methylprednisolone tablets, no more than 84 mg per package.
- Prednisone tablets, no more than 105 mg per package.
- Betamethasone tablets, no more than 12.6 mg per package.
- Mebendazole tablets, no more than 600 mg per package.
- Sodium fluoride products, no more than 264 mg per package.
- Potassium supplements in unit-dose forms, no more than 50 mEq per unit dose.
- Anhydrous cholestyramine and colestipol powders.
- Erythromycin ethylsuccinate granules and tablets, within the package limits.
- Pancrelipase preparations and sacrosidase solution.
- Aerosol products for inhalation.
Exemptions are tied to the package. A methylprednisolone dose pack of 21 × 4 mg (84 mg) is exempt. A 100-count bottle of 4 mg tablets dispensed in a vial is not.
Other packaging rules
- Hospital inpatients receiving drugs administered by staff don't need special packaging. Drugs dispensed to patients for home use do.
- Med paks (OAR 855-041-1140) must comply with the PPPA, or the patient must have waived child-resistant packaging, and must use Class B containers.
- Repackaged drugs must use USP-compliant containers (OAR 855-041-1135).
- Unit-dose packaging may omit the physical description on the label (OAR 855-041-1130(12)), but PPPA rules still apply to drugs dispensed for home use.
- Light- and moisture-sensitive drugs must be packaged as the manufacturer or USP specifies (OAR 855-041-1036).
Nonprescription drugs
Many OTC drugs also need special packaging, such as aspirin, acetaminophen, iron-containing products and diphenhydramine. A manufacturer of an OTC product subject to the PPPA may market one size in non-child-resistant packaging if it is conspicuously labeled "This package for households without young children" and the product is also available in child-resistant packaging. Section 9.1 covers OTC labeling.
Documenting waivers in practice
PPPA waivers are easiest to defend when they are documented. Oregon doesn't prescribe a waiver form, but good practice and most inspection expectations follow this pattern:
- Record who asked. Note in the patient profile that a blanket request came from the patient or agent, or that the prescriber requested non-child-resistant packaging for a particular prescription.
- Record the scope. A patient's request may cover all prescriptions or only some. A prescriber's request covers only the prescription, and its refills, on which it appears.
- Revisit it when circumstances change. If a grandchild moves into the home, counsel the patient that child-resistant packaging can be restored at any time.
- Check the technology. Pharmacy software that defaults to easy-open caps for a patient must reflect an actual request from the patient. A system setting is not a waiver.
The pharmacist remains responsible for the finished prescription, including its container. That holds even when a technician performs final product verification, because the pharmacist still verifies the label and the other elements beyond the drug-and-dose match (OAR 855-115-0130(3)).
Important
A prescriber's checkbox saying "all future prescriptions in easy-open caps" does not create a blanket waiver. Only the patient may make a blanket request. The prescriber's request covers the specific prescription.
Exam scenario
An 82-year-old with severe arthritis receives four new prescriptions:
- Prednisone 10 mg #30.
- Sublingual nitroglycerin.
- A methylprednisolone 4 mg dose pack.
- Atorvastatin.
She asks for easy-open caps on everything. With her request, all four may be dispensed in non-child-resistant packaging, and the pharmacy records her blanket request. Without it, nitroglycerin SL and the 84 mg dose pack are exempt. Prednisone 10 mg #30 (300 mg) exceeds the 105 mg exemption, so it needs a child-resistant closure, and so does atorvastatin. Each must go in a new container.
A physician writes on a new prescription: 'Dispense this and all future prescriptions for this patient in non-child-resistant caps.' How should an Oregon pharmacist apply this?
Honor it for all future prescriptions; prescribers may waive packaging permanently
Ignore it; only the pharmacist decides packaging
Apply it to this prescription only; a blanket waiver for all prescriptions can come only from the patient
Refuse to fill until the CPSC approves the waiver
Which dispensed product requires child-resistant packaging absent a waiver?
Sublingual nitroglycerin tablets
Prednisone 20 mg #20 in a prescription vial
A methylprednisolone 4 mg dose pack containing 84 mg total
Oral contraceptives in the manufacturer's mnemonic dispenser
A patient brings back a clean amber glass vial and asks that her refill go into it. What does Oregon law require?
Dispense the refill in a new container meeting PPPA requirements, as OAR 855-041-1145 requires
Reuse the vial with a new child-resistant cap
Reuse the vial if the patient signs a waiver
Reuse the vial for non-controlled drugs only
Sections you finish are checked off in the contents.